Literature DB >> 10563602

Multiple sclerosis: side effects of interferon beta therapy and their management.

E U Walther1, R Hohlfeld.   

Abstract

Article abstract-Interferon beta (IFNbeta) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNbeta may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNbeta-1b and IFNbeta-1a. Possible side effects of IFNbeta include various autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia, and depression. We discuss the mechanisms and management of the different side effects of IFNbeta.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10563602     DOI： 10.1212/wnl.53.8.1622

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  70 in total

1.  Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling.

Authors:  Fabienne Rehren; Barbara Ritter; Oliver Dittrich-Breiholz; Andreas Henke; Elena Lam; Semra Kati; Michael Kracht; Albert Heim
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

Review 2.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 3.  [Interferon therapy of multiple sclerosis. Synopsis of various dosage forms].

Authors:  S Jarius; R Hohlfeld
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

4.  Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.

Authors:  V Christopher; N Scolding; R T Przemioslo
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

5.  Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.

Authors:  S S O'Sullivan; E M Cronin; B J Sweeney; J F Bourke; J Fitzgibbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-16       Impact factor: 10.154

6.  Mononeuropathy following subcutaneous interferon-beta injection.

Authors:  M Capasso; M Caulo; G De Luca; N Magarelli; A Lugaresi
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 7.  Why health expectations and hopes are different: the development of a conceptual model.

Authors:  Karen K Leung; James L Silvius; Nicholas Pimlott; William Dalziel; Neil Drummond
Journal:  Health Expect       Date:  2009-08-18       Impact factor: 3.377

8.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 9.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 10.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.